- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
On Wednesday, Verrica Pharmaceuticals Inc (VRCA:NMQ) closed at 7.50, -34.27% below its 52-week high of 11.41, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.52 |
---|---|
High | 7.67 |
Low | 7.30 |
Bid | 4.30 |
Offer | 8.68 |
Previous close | 7.47 |
Average volume | 323.33k |
---|---|
Shares outstanding | 42.42m |
Free float | 20.49m |
P/E (TTM) | -- |
Market cap | 318.15m USD |
EPS (TTM) | -1.75 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼